AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
BKD

Brookdale Senior Living Inc. Common Stock (BKD) fair value

Healthcare · Medical Care Facilities · NYSE · United States
$10.08-1.08%
Market cap $2.4BNext earnings 2026-11-05Updated Oct 19, 2026
Add earnings to calendarGoogle
Our verdict
Trades 2511% above our fair value
Price
$10.08
Model fair valueConfidence: low
about $0.39
Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a mature, profitable company: Discounted cash flow.
ACCE opinionBrookdale Senior Living Inc. Common Stock (BKD)
Fair value (2 models)
Not available
ACCE price target
$9.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Price used: $10.08 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
25
out of 100
Analysts
100% buy
6 covering
1-year return
+15.6%
Dividend yield
0.00%

Brookdale Senior Living Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Brookdale Senior Living operates assisted living, memory care, independent living and continuing care retirement communities across the US, earning resident fees that make it one of the largest senior living operators by unit count. The structural case rests on demographics: the 80-plus population is growing faster than the overall population, and the company's scale in occupancy-driven care is the main thing a smaller operator can't replicate. Against that, revenue fell 8.9% and the 6.8% operating margin is thin for a business carrying this much fixed-cost real estate, and the -349.6% ROE reflects a balance sheet with little equity left to absorb another downturn. The forward P/E of 45.7 implies the market is pricing a sharp earnings recovery that has not yet shown up in reported results, so the question for a deeper look is whether occupancy and rate gains can restore margins before the debt load becomes the binding constraint. The score of 25/100 and absence from major indices suggest the screens already see this as a turnaround candidate, not a compounder.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 5 flagsAI-assisted·How I use AI
  • severe
    Leverage far beyond equity
    Debt/Equity of -148.91 and ROE of -349.6% show negative book equity, with FCF of only $17M against a $2.4B market cap. Capital structure is fragile.
  • high
    Heavy short interest
    Short interest stands at 19.1% of float, a large bet against the shares that signals serious skepticism about the balance sheet and earnings.
  • high
    Revenue shrinking year over year
    Revenue fell 8.9% YoY, and earnings were flat. A five-year revenue CAGR of only 0.7% points to a business that is not growing.
  • moderate
    Score down sharply in 90 days
    ACCE score fell from 36 to 25 over 90 days, with the quality and value sub-scores weak at 26 and 28.
  • moderate
    Price above ACCE target
    The stock trades 12.0% above the ACCE price target of $9.00, with the current price at $10.08.

AI research notes

AI-assisted·How I use AIWritten Oct 22, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Six of six analysts rate the stock Buy or Strong Buy, and their mean price target sits well above the current price.
  • The latest quarter beat expectations, with earnings per share of 0.10 against an expected loss of 0.04.
  • The company generated 17M in free cash flow over the last twelve months, a sign the business can fund itself.
Why it could disappoint
  • Revenue fell 8.9% year over year, and the five-year average growth rate is only 0.7% per year.
  • The company has negative equity and a return on equity of -349.6%, leaving little cushion for shareholders.
  • At 84.0x forward earnings and a 0.7% free cash flow yield, the price already assumes very strong future growth.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where BKD's valuation models land
Price
$10.08
Model fair valueConfidence: low
about $0.39
Model
Fair value
Upside
Discounted cash flow
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bullish100% buy · 6 covering analysts
● Strong buy 4● Buy 2● Hold 0● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
-0.1%
1 month
-9.8%
3 months
-33.5%
6 months
-27.4%
YTD
-6.6%
1 year
+15.6%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
11 Oct 2026, 00:00 CESTACCE price target$9.00first publication$10.12
10 Sept 2026, 00:00 CESTFair value$0.66$0.65$12.09
30 Aug 2026, 00:00 CESTFair value$0.65$0.63$11.72
27 Aug 2026, 00:00 CESTFair value$0.63$0.65$12.11
25 Aug 2026, 00:00 CESTFair value$0.65$0.62$11.85
20 Aug 2026, 00:00 CESTFair value$0.62first publication$12.13

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full BKD page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth7Value28Quality26Momentum39Total25
Valuation
Trailing P/E
no data
Forward P/E
84.0x
PEG
no data
P/B
18.98x
EV / Revenue
2.5x
Book value/sh
$-0.12
Enterprise value
$7.8B
Profitability
ROE
-349.6%
FCF yield
0.69%
ROIC
no data
Health and risk
Debt / equity
-148.91
Dividend yield
0.00%
Beta
0.53

Price

+14.2% · 1Y

Ask anything about BKD

Answered from Brookdale Senior Living Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
ROEbetter than 0% of peers
low -350%-350%high 199%
Div yieldbetter than 100% of peers
low 0.0%0.0%high 0.0%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
BKD Brookdale Senior Living Inc. Common Stock$10.08----349.6%2625
MD Pediatrix Medical Group Inc. Common Stock$29.29$2325% above13.3x20.4%6974
GRDN Guardian Pharmacy Services Inc. Class A Common Stock$39.44$2375% above38.3x30.4%6761
ADUS Addus HomeCare Corporation Common Stock$121.81$1138% above21.3x9.7%6366
SGRY Surgery Partners Inc. Common Stock$15.75$1052% above-2.3%3343
AVAH Aveanna Healthcare Holdings Inc. Common Stock$13.38$143% below10.6x198.6%6077
ACHC Acadia Healthcare Company Inc. Common Stock$31.51----41.4%4348

Sector report card

Where BKD ranks against its sector peers on each metric.

Computing percentiles…
  • PR Newswire•Oct 13, 2026
    Brookdale Completes Acquisition of 17 Communities and Announces Mutually Beneficial Agreement to Acquire 30 Additional Leased Communities from Welltower
  • PR Newswire•Oct 8, 2026
    Brookdale Reports September 2026 Occupancy
  • PR Newswire•Sep 17, 2026
    Brookdale CEO Nick Stengle Receives Champion for Aging Award
4 more press releases · full archive on Investor+.INVESTOR
36 filings of 38
October 2026
Oct 8
8-KCurrent reportPeriod 2026-10-08
View on SEC →
Oct 7
Form 4Insider transactionPeriod 2026-10-06
View on SEC →
August 2026
Aug 10
8-KCurrent reportPeriod 2026-08-10
View on SEC →
33 more filings + AI summaries on Investor+.INVESTOR